Advertisement
MDT vs SYK
Which Stock Would AI Choose? Medtronic (MDT) vs. Stryker (SYK) Stock Comparison
Key Takeaways
- Medtronic (MDT) and Stryker (SYK) are leading medical device companies with overlapping exposure to orthopedics, robotics, and surgical technologies, though MDT maintains a broader portfolio across cardiology, neuroscience, and diabetes.
- In recent market activity, both stocks have traded near 52-week lows amid sector pressures, with MDT closing at approximately $73.81 and SYK at $305.09 as of late May 2026.
- MDT faces an upcoming fiscal Q4 earnings report on June 3, 2026, with analyst estimates pointing to revenue growth but a modest year-over-year EPS decline.
- SYK reported Q1 2026 results that missed revenue expectations but maintained full-year organic sales growth guidance of 8%-9.5%.
- MDT offers a higher dividend yield compared with SYK, while SYK has historically shown stronger long-term growth in select segments such as robotics.
- Relative performance in recent weeks has been mixed, with both names lagging broader market gains amid regulatory and macroeconomic headwinds in healthcare.
Introduction
Medtronic (MDT) and Stryker (SYK) represent two prominent players in the global medical technology sector, making them natural candidates for comparison by investors seeking exposure to healthcare equipment and supplies. Both companies develop and commercialize devices used in surgical procedures, orthopedics, and minimally invasive interventions, yet they differ in portfolio breadth, growth drivers, and capital return profiles. This comparison is particularly relevant for institutional and retail investors focused on relative performance, dividend sustainability, and positioning within the medtech space during periods of market volatility. Traders monitoring sector rotation or AI-driven signals may also find value in assessing how recent catalysts have influenced each name’s momentum and valuation metrics.
MDT Overview and Recent Performance
Medtronic plc (MDT) is a diversified medical device manufacturer with operations spanning cardiac and vascular, medical-surgical, neuroscience, and diabetes care segments. In recent weeks, the stock has experienced downward pressure, closing near its 52-week low amid elevated trading volume and ahead of its fiscal fourth-quarter earnings release. Analysts project revenue of $9.66 billion for the quarter, reflecting approximately 8.3% year-over-year growth, while EPS is estimated at $1.54, down modestly from the prior year. Recent developments include leadership transitions within the neuroscience portfolio and continued regulatory milestones, such as CE mark approvals for certain surgical systems. Market sentiment has been tempered by broader healthcare sector caution and upcoming earnings uncertainty, contributing to the observed price consolidation.
SYK Overview and Recent Performance
Stryker Corporation (SYK) specializes in orthopedics, medical and surgical equipment, and neurotechnology, with notable strength in robotic-assisted surgery platforms. The stock reached new 52-week lows during May 2026 following its first-quarter earnings release, which showed reported net sales of $6.02 billion, up 2.6% year-over-year but below consensus estimates. Despite the revenue miss, the company maintained its full-year 2026 organic sales growth outlook of 8%-9.5% and adjusted EPS range of $14.90-$15.10. Recent market activity reflects investor digestion of the earnings shortfall alongside recovery from a prior cyber incident. Sentiment has remained measured, supported by the reaffirmed guidance yet tempered by short-term momentum weakness relative to the broader market.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing AI trading bots from hundreds available across the platform. These bots trade thousands of different tickers using varied strategies, timeframes, and performance statistics tailored to current market conditions. Only the most suitable and robust bots earn placement in the trending section, which highlights available performance ranges and statistical profiles to assist users in identifying relevant automated trading solutions. All AI trading bots differ in style, risk parameters, and ticker coverage. For further details on these tools, visit the Trending AI Robots page.
Head-to-Head Comparison
Medtronic (MDT) operates a more diversified business model across multiple therapeutic areas, providing broader revenue stability but exposing it to varied regulatory and reimbursement dynamics. Stryker (SYK) concentrates on high-growth areas such as orthopedic implants and robotic systems, offering stronger potential upside from adoption trends yet greater sensitivity to procedural volume fluctuations. In recent market activity, MDT has demonstrated relative resilience in dividend support, while SYK’s momentum has been more affected by its earnings miss. Risk factors include MDT’s upcoming earnings release and SYK’s ongoing recovery from operational disruptions. Sector exposure remains comparable within healthcare equipment, though MDT’s larger scale may confer advantages in supply chain and R&D diversification. Market sentiment currently favors neither decisively, with both names reflecting cautious positioning amid macroeconomic pressures on healthcare spending.
Tickeron AI Verdict
Based on observable factors such as trend consistency, valuation metrics, and relative stability signals, Tickeron’s AI currently assigns a probabilistic edge to Medtronic (MDT) over Stryker (SYK) in the near term. MDT’s broader portfolio and upcoming earnings visibility may support steadier positioning compared with SYK’s recent momentum dip following its quarterly results. This assessment reflects data-driven probabilities rather than certainty and does not constitute investment advice.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDT is a StrongBuy and SYK is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MDT’s FA Score shows that 1 FA rating(s) are green whileSYK’s FA Score has 1 green FA rating(s).
- MDT’s FA Score: 1 green, 4 red.
- SYK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MDT’s TA Score shows that 5 TA indicator(s) are bullish while SYK’s TA Score has 5 bullish TA indicator(s).
- MDT’s TA Score: 5 bullish, 4 bearish.
- SYK’s TA Score: 5 bullish, 3 bearish.
Price Growth
MDT (@Medical/Nursing Services) experienced а +10.65% price change this week, while SYK (@Medical/Nursing Services) price change was +0.19% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.83%. For the same industry, the average monthly price growth was +0.22%, and the average quarterly price growth was -16.42%.
Reported Earning Dates
MDT is expected to report earnings on Aug 25, 2026.
SYK is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Medical/Nursing Services (-1.83% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| MDT | SYK | MDT / SYK | |
| Capitalization | 105B | 117B | 90% |
| EBITDA | 9.36B | 6.31B | 148% |
| Gain YTD | -14.286 | -12.798 | 112% |
| P/E Ratio | 21.90 | 35.38 | 62% |
| Revenue | 35.5B | 25.1B | 141% |
| Total Cash | 8.38B | N/A | - |
| Total Debt | 28.1B | 15.9B | 177% |
MDT | SYK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 14 | 29 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 3 Undervalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 67 | |
SMR RATING 1..100 | 75 | 57 | |
PRICE GROWTH RATING 1..100 | 58 | 61 | |
P/E GROWTH RATING 1..100 | 61 | 82 | |
SEASONALITY SCORE 1..100 | 50 | 37 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MDT's Valuation (3) in the Medical Specialties industry is in the same range as SYK (10). This means that MDT’s stock grew similarly to SYK’s over the last 12 months.
SYK's Profit vs Risk Rating (67) in the Medical Specialties industry is somewhat better than the same rating for MDT (100). This means that SYK’s stock grew somewhat faster than MDT’s over the last 12 months.
SYK's SMR Rating (57) in the Medical Specialties industry is in the same range as MDT (75). This means that SYK’s stock grew similarly to MDT’s over the last 12 months.
MDT's Price Growth Rating (58) in the Medical Specialties industry is in the same range as SYK (61). This means that MDT’s stock grew similarly to SYK’s over the last 12 months.
MDT's P/E Growth Rating (61) in the Medical Specialties industry is in the same range as SYK (82). This means that MDT’s stock grew similarly to SYK’s over the last 12 months.
| MDT | SYK | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 60% | 3 days ago 54% |
| Stochastic ODDS (%) | 3 days ago 45% | 3 days ago 63% |
| Momentum ODDS (%) | 3 days ago 55% | 3 days ago 58% |
| MACD ODDS (%) | 3 days ago 43% | 3 days ago 62% |
| TrendWeek ODDS (%) | 3 days ago 51% | 3 days ago 53% |
| TrendMonth ODDS (%) | 3 days ago 45% | 3 days ago 47% |
| Advances ODDS (%) | 4 days ago 51% | 3 days ago 55% |
| Declines ODDS (%) | 10 days ago 57% | 6 days ago 53% |
| BollingerBands ODDS (%) | 3 days ago 47% | 3 days ago 64% |
| Aroon ODDS (%) | 3 days ago 48% | 3 days ago 46% |
Advertisement
MDT and
Correlation & Price change
A.I.dvisor indicates that over the last year, MDT has been loosely correlated with SYK. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if MDT jumps, then SYK could also see price increases.
SYK and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYK has been loosely correlated with ISRG. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SYK jumps, then ISRG could also see price increases.